Home » Authors » Douglas Merrill

Articles by Douglas Merrill

Insurance Costs Prompt Mass Exodus From LION Bioscience

Oct. 20, 2004

By Douglas Merrill

Preclinical Alzheimer's Data Trigger Change At Sirenade

Oct. 20, 2004

By Douglas Merrill

Public, Private Sectors At Odds Over German Biotech Direction

Sep. 29, 2004

By Douglas Merrill

Public, Private Sectors At Odds Over German Biotech Direction

Sep. 29, 2004

By Douglas Merrill

Intercell's Start-Up Biovertis Receives EUR12M In Series A

Sep. 8, 2004

By Douglas Merrill

Intercell's Start-Up Biovertis Receives EUR12M In Series A

Sep. 8, 2004

By Douglas Merrill

Intercell's Hepatitis C Vaccine Gets Positive Phase II Results

July 28, 2004

By Douglas Merrill

Intercell's Hepatitis C Vaccine Gets Positive Phase II Results

July 28, 2004

By Douglas Merrill

Trying To Open German Biotech Market, Epigenomics Seeks IPO

July 7, 2004

By Douglas Merrill

Trying To Open German Biotech Market, Epigenomics Seeks IPO

July 7, 2004

By Douglas Merrill

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...